Free Oncology CME | CMEList.com

 


Hospital Medicine CME Online Bundle: Clinical Update - Journal Summaries - $400 Amazon.com Gift Card Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly--Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care Free Melnonoma CME 
Posted by...Bernard Sklar, MD.
Free Oncology and Dermatology CME Credit Hours...1.25.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.
Educational material updated...December 4, 2017.
Expiration of CME credit...December 4, 2019.
Financial Support...Promethius.
Metastatic Melanoma: Novel Approaches discusses the epidemiology, causes, clinical features, pathogenesis and immunotherapy in the treatment of metastatic melanoma.
By the end of Metastatic Melanoma: Novel Approaches, you will be able to:
• Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
• Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Describe emerging (investigational) therapies for metastatic melanoma
• Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

Oncology Patients at High Risk of Bone Fracture: Advances in Pharmacotherapy Free Oncology CME
Posted by...Bernard Sklar, MD.
Free Oncology and Endocrinology CME Credit Hours...0.75.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.
Educational material updated...November 17, 2017.
Expiration of CME credit...November 17, 2019.
Financial Support...Amgen.
The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients. 
By the end of Oncology Patients at High Risk of Bone Fracture, you will be able to:
• Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
• Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
Identify present pharmacotherapeutic treatments for management of a patient receiving • AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
• Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case

Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics Free Oncology CME
Live online October 20, 2017 and available on demand until April 20, 2018.
Posted by...Bernard Sklar, MD.
Free Oncology and Gynecology CME Credit hours..1.0.
CME Credits Awarded by....Postgraduate Institute for Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for Medical and gynecologic oncologists, oncology nurses, nurse practitioners, pharmacists, and other health care professionals, including gynecologists, primary care physicians, physicians-in-training, and physician assistants involved in and/or interested in the management of patients with ovarian cancer.
Educational material updated...October 20, 2017.
Expiration of CME credit...April 20, 2018.
Financial Support...Clovis Oncology and AbbVie.
Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics consists of a single presentation with discussion featuring Drs. Bradley J. Monk, MD and Robert L. Coleman, MD.
At the conclusion of Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics , you will be able to:
• Appraise the pathophysiology of ovarian cancer and their associated mutations, including germline and somatic BRCA mutations and other DNA repair deficiencies such as loss of heterozygosity
• Evaluate the safety and efficacy data of PARP inhibitors
• Use the latest diagnostic tools and genetic testing to identify patients who would benefit from PARP inhibitor therapy

Advances in Treating Metastatic Colorectal Cancer (CRC): Optimizing Recognition and Pharmacotherapeutic Management Strategies Free Oncology CME Free Gastroenterology CME
Posted by...Bernard Sklar, MD.
Free Oncology and Gastroenterology CME Credit Hours...1.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.
Educational material updated...October 19, 2017.
Expiration of CME credit...October 19, 2019.
Financial Support...Amgen
Advances in Treating Metastatic Colorectal Cancer (CRC) discusses the diagnosis and treatment of metastatic colorectal cancer (mCRC).
By the end of Advances in Treating Metastatic Colorectal Cancer (CRC) , you will be better able to:
• Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
• Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
• Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
• Describe the challenges and barriers to care associated with treating patients with mCRC
In order to receive credit from ScientiaCME, you must first establish a username and password.

Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy Free oncology CME Free Hematology CME
Posted by...Bernard Sklar, MD.
Free Oncology and Hematology CME Credit Hours...1.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.
Educational material updated...November 02, 2017.
Expiration of CME credit...November 02, 2019.
Financial Support...Amgen
The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.
By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy , you will be able to:
• Recall updates in the staging, prognosis, and diagnosis of MM.
• Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
• Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

New Horizons in Personalized Care for Metastatic Bladder Cancer Free Diabetes CME
Live online August 11, 2017 and available on demand through February 11, 2018.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..1.0.
CME Credits Awarded by....Albert Einstein College of Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for Medical/genitourinary oncologists, urologists, surgeons, radiologists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with bladder cancer.
Educational material updated...August 11, 2017.
Expiration of CME credit...February 11, 2018.
Financial Support...Genentech.
New Horizons in Personalized Care for Metastatic Bladder Cancer consists of a single lecture, New Horizons in Personalized Care for Metastatic Bladder Cancer with discussion by Matthew I. Milowsky, MD and Matthew Galsky, MD. 
After viewing New Horizons in Personalized Care for Metastatic Bladder Cancer, you will be better able to :
• Evaluate the role of new targeted and immune-based agents in the first- and second-line metastatic settings, and how they can be integrated into practice
• Apply strategies and tools that enhance patient-clinician communication and shared decision making processes

Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions
Live online August 24, 2017 and available on demand through February 24, 2018. 
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..2.0.
CME Credits Awarded by....Postgraduate Institute for Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for medical and radiation oncologists, head and neck surgeons, otolaryngologists, ear, nose and throat (ENT) specialists, and other health care professionals (primary care providers, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with head and neck cancer.
Educational material updated...August 24, 2017.
Expiration of CME credit...February 24, 2018.
Financial Support...Bristol-Myers Squibb and Merck & Co..
Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions consists of two lectures with discussion, Effective Management Strategies for Head and Neck Cancer and The New Paradigm of Immunotherapy for Head and Neck Cancer, both with Robert I. Haddad, MD and Jared Weiss, MD. 
After viewing Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions, you will be better able to :
• Assess the safety and efficacy of available and emerging multimodal regimens, including immunotherapy, for patients with head and neck cancer
• Utilize strategies to optimally sequence available regimens for the therapeutic management of head and neck cancer
• Evaluate the latest clinical efficacy and safety data on the use of immune checkpoint inhibitors in head and neck cancer
• Examine anticipated adverse events related with immune checkpoint inhibitors in head and neck cancer

Emerging Therapies for Relapsed/Refractory Multiple Myeloma Free Multiple Myeloma CME
Live online September 13, 2017 and available on demand through March 13, 2018.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..1.0.
CME Credits Awarded by....University of Nebraska Medical Center, Center for Continuing Education.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for US-based hematologist-oncologists, oncologists, oncology nurses, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients with multiple myeloma.
Educational material updated...September 13, 2017.
Expiration of CME credit...March 13, 2018.
Financial Support...AbbVie, Karyopharm Therapeutics Inc., and Merck Sharp & Dohme Corp.
Emerging Therapies for Relapsed/Refractory Multiple Myeloma consists of a single lecture, Emerging Therapies for Relapsed/Refractory Multiple Myeloma, with discussion by Ravi Vij, MD, MBA and David Dingli, MD, PhD. 
After viewing Emerging Therapies for Relapsed/Refractory Multiple Myeloma , you will be better able to :
• Identify disease-related, patient-related, and cytogenetic factors that shape treatment decisions for the management of relapsed/refractory MM
• Examine safety and efficacy data of emerging strategies for patients with MM who have received prior lines of therapies including proteasome inhibitors and immunomodulatory agents
• Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
• Discuss the therapeutic implications of combination regimens involving emerging agents with currently available treatment option 

Metastatic Melanoma: Updates from ASCO 2017 Free Melanoma CME Posted by...Bernard Sklar, MD.
Free Oncology CME Credit Hours...1.0.
CME Credits Awarded by....ScientiaCME.
Cost..........Free. 
Instruction Type....Slide-Video Lectures.
Target Audiences...Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.
Educational material last updated...September 19 2017.
Expiration of CME credit....September 19, 2019.
Financial Support...Amgen.
Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges.
Metastatic Melanoma: Updates from ASCO 2017 summarizes major findings from ASCO 2017 related to Metastatic Melanoma, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice
After reviewing Metastatic Melanoma: Updates from ASCO 2017 you will be able to:
• Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.

Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors Free Oncology CME
Live online June 28, 2017 and available on demand through December 28, 2017.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..1.0.
CME Credits Awarded by....Albert Einstein College of Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for medical, radiation and surgery oncologists, breast surgeons, oncology nurse practitioners, pharmacists, and other health care professionals who treat patients with breast cancer.
Educational material updated...June 28, 2017.
Expiration of CME credit...December 28, 2017.
Financial Support...Novo Nordisk.
Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors consists of a single lecture, with discussion, by Richard S. Finn, MD. 
After viewing Hormone Receptor-Positive Advanced/Metastatic Breast Cancer, you will be better able to :
• Address the current advances and challenges of treating HR+, HER2- advanced and metastatic breast cancer
• Evaluate new safety and efficacy data of CDK4/6 inhibitors for HR+, HER2- advanced and metastatic breast cancer
• Anticipate and plan effective strategies to manage CDK4/6 inhibitor treatment-related side effects

Risky Business: Diagnosing and Treating Invasive Fungal Infections
Free Fungal Infection CME Posted by...Bernard Sklar, MD.
Free CME Credit Hours...1.0.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Hematologist-oncologists, medical oncologists, transplant surgeons, critical care surgeons, critical care pulmonologists, and other health care professionals involved in the treatment of patients with or at risk for invasive fungal infections.
Educational material last updated...April 18, 2017.
CME Credit Expires...April 17, 2018.
Financial Support...Astellas.
Risky Business: Diagnosing and Treating Invasive Fungal Infections consists of 3 brief lectures on the diagnosis and treatment of invasive fungal infection:
After completing Risky Business: Diagnosing and Treating Invasive Fungal Infections, you should be better able to:
• Describe the epidemiology and burden of invasive fungal infections in patients who are immunocompromised and/or Immunosuppressed.
• Incorporate the latest diagnostic techniques for invasive fungal infections to ensure that the appropriate therapy can be initiated in a timely manner.
• Integrate the latest evidence-based treatment guidelines and clinical data pertaining to the efficacy, safety, and prophylactic use of antifungal agents to optimize the management of invasive fungal infections.

Test your knowledge of interventional oncology Oncology CME
Posted by...Bernard Sklar, MD.
Oncology CME CME Credit hours 3.25 total (for all 7 modules). 
CME Credits Awarded by....The France Foundation in collaboration with the Society of Interventional Oncology.
Cost...........Free.
Instruction Type...Slide-Video Lecture.
Target Audiences...Clinicians practicing interventional oncology (IO) or those who are interested in learning more about IO. 
Educational material updated....October 2017.
Expiration of CME credit...October 2018.
Financial Support...Bayer Healthcare, Biocompatibles, Inc., Boston Scientific, Guerbet LLC, and Medical Device Business Services, Inc. (Ethicon).
Earn CME with these new modules on lung cancer which include education on advances in lung cancer treatment, surgical and radiofrequency-ablative techniques, targeted therapies, and immunotherapies. Each takes less than 30 minutes to complete!  Visit IO University to access this free education now!

Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment Free Diabetes CME
Live online June 14, 2017 and available on demand through June 14, 2018.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..1.0.
CME Credits Awarded by....University of Nebraska Medical Center, Center for Continuing Education
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome.
Educational material updated....June 14, 2017.
Expiration of CME credit...June 14, 2018.
Financial Support...Lexicon Pharmaceuticals, Inc..
Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment consists of a single lecture and discussion by Drs. Matthew H. Kulke and C. Metz.
After viewing Carcinoid Syndrome, you will be better able to :
• Summarize the cause of carcinoid syndrome
• Perform an appropriate workup and differential diagnosis from presenting symptoms
• Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
• Evaluate safety and efficacy of current and emerging treatment approaches for carcinoid syndrome

ScientiaCME Hematology/ Oncology  ScientiaCME Oncology  
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit Hours...7.25.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...HEMATOLOGY.
CME Credit Expires...Two years after release.
Financial Support...Various commercial supporters.

Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma Free Pediatric Neuroblastoma CME
Live online August 4, 2017 and September 29, 2017 and available on demand until September 29, 2018.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..2.0.
CME Credits Awarded by....Postgraduate Institute for Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for pediatric oncology nurses, pediatric nurses, oncology nurses, nurse practitioners, nurse managers, infusion nurses, research nurses, physician assistants, and other health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma.
Educational material updated...September 29, 2017.
Expiration of CME credit...September 29, 2018.
Financial Support...United Therapeutics Corporation.
Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma consists of two presentations with discussion: Optimal Nursing Strategies to Manage Pediatric Patients with High-Risk Neuroblastoma and Recurrent/Refractory Disease of Pediatric Neuroblastoma: Enhancing the Role of the Nurse.
At the conclusion of Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you will be able to:
• Review the fundamentals of diagnosing, treating, and managing high-risk pediatric neuroblastoma
• Examine strategies to improve supportive care for children with high-risk neuroblastoma
• Examine the aspects of parental decision-making regarding appropriate care for children with recurrent/refractory neuroblastoma
• Plan strategies to improve the dialogue and working relationship with parents/caregivers of pediatric patients regarding the goals of care through the treatment continuum and beyond
Nursing Educational Objective:
After completing Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you should be able to:
• Provide appropriate care and counsel for patients and their families